U.S. markets closed
  • S&P 500

    4,544.90
    -4.88 (-0.11%)
     
  • Dow 30

    35,677.02
    +73.94 (+0.21%)
     
  • Nasdaq

    15,090.20
    -125.50 (-0.82%)
     
  • Russell 2000

    2,291.27
    -4.92 (-0.21%)
     
  • Crude Oil

    83.98
    +1.48 (+1.79%)
     
  • Gold

    1,793.10
    +11.20 (+0.63%)
     
  • Silver

    24.39
    +0.22 (+0.91%)
     
  • EUR/USD

    1.1648
    +0.0018 (+0.15%)
     
  • 10-Yr Bond

    1.6550
    -0.0210 (-1.25%)
     
  • GBP/USD

    1.3759
    -0.0036 (-0.26%)
     
  • USD/JPY

    113.4600
    -0.5280 (-0.46%)
     
  • BTC-USD

    60,671.93
    -1,793.93 (-2.87%)
     
  • CMC Crypto 200

    1,453.34
    -49.69 (-3.31%)
     
  • FTSE 100

    7,204.55
    +14.25 (+0.20%)
     
  • Nikkei 225

    28,804.85
    +96.27 (+0.34%)
     

Invo Bioscience Stock Rallies After Amended Agreement Expands Company-Owned Clinics In US

·1 min read

Invo Bioscience Inc (NASDAQ: INVO) shares have gained sharply after an amendment under its exclusive U.S. commercialization agreement with Ferring Pharmaceuticals.

  • The amendment provides an increase in the number of INVO company-owned clinics initially allowable under the agreement and removes certain geographical restrictions.

  • Invo's lead product, the INVOcell is a medical device used in infertility treatment and is considered an Assisted Reproductive Technology.

  • Steve Shum, CEO of INVO Bioscience, said, "we believe it reflects the strength of our ongoing collaboration and shared commitment to expand the use of INVOcell in the U.S."

  • The amendment also adjusted the remaining annual 2020 minimum contractual product purchase requirement, whereby Ferring will place a $501,000 order.

  • It will be recognized as revenue by INVO Bioscience in the first quarter of 2021.

  • Price Action: INVO shares increased 94.9% at $6.12 in premarket trading on the last check Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.